The possibility of using lncRNAs as oncological biomarkers has not only been tested, but also turned into a reality with the FDA-approved test PROGENSA® PCA3 assay by Gen-Probe Inc. for prostate cancer diagnosis, which is entirely based on the detection of lncRNA PCA3 in patient urine (87–89). Here, PCA3 is linked to prostate carcinoma.